A drug called Kadcyla has been shown to cut the chance of breast cancer recurrence by half for women whose cancer is HER2+.
Roughly 20% of women with breast cancer have HER2+ cancer cells, and part of the treatment regimen typically includes Herceptin, an antibody that has been available to cancer patients for over two decades now. It specifically targets HER2+ cancer cells, and is already proven to prevent recurrence.
Kadcyla (T-DM1) is actually a combination of two drugs: Herceptin (known generically as trastuzumab) and emtansine. Emtansine is a type of chemotherapy. When combined with Herceptin, emtansine delivers a double-punch to cancer cells.
“The chemotherapy is attached to the antibody,” Dr. Charles Geyer, lead researcher on the study, explains. “The idea is that the antibody will carry the chemo directly into the cells that you want to hit.”
The current standard of treatment for early-stage, HER2-positive breast cancer is traditional chemotherapy followed by Herceptin, and then surgery to remove any remaining cancerous cells. It’s often successful in eliminating all evidence of cancer. However, many women do still have cancer when they undergo surgery, and they have a higher-than-usual risk of the cancer returning.
The current best practice for women who do still have cancerous cells at the time of surgery is to have them continue to take Herceptin for a year afterwards.
Article continues below
Our Featured Programs
See how we’re making a difference for People, Pets, and the Planet and how you can get involved!
This study aimed to find out if Kadcyla would be a more effective treatment than Herceptin for women who still had those cancerous cells remaining after surgery.
The study was published in the New England Journal of Medicine on December 5, 2018.
There were 1,486 women enrolled in the study. After every woman went through the standard treatment regimen described above, they were randomly split into two groups: 743 were given Kadcyla and 743 were given Herceptin. Every three weeks, they were given an infusion of their assigned drug. This lasted for 14 cycles.
The study found that Kadcyla increased chance of survival significantly. Three years after the treatment, 88% of the women who took Kadcyla were still living and cancer-free, compared to 77% of the women who took Herceptin.
Grade 3 or higher side effects were more prevalent in women who took Kadcyla than in women who took Herceptin. For those taking Kadcyla, the most common side effects were thrombocytopenia (low platelet count) in 5.7% of patients and hypertension (high blood pressure) in 2.0% of patients. For those taking Herceptin, the most common side effects were hypertension in 1.2% of patients, and radiation-related skin injury in 1.0% of patients.
For women with HER2+ breast cancer, this is incredible news. While Kadcyla is not approved to treat patients who are like the women in the study, it is already FDA-approved — and doctors are able to freely prescribe FDA-approved drugs for reasons other than what they’re officially meant for. It’s just a matter of making sure that your insurance agrees.Whizzco